{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:41:04Z","timestamp":1777635664387,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Without a vaccine, hepatitis C virus (HCV) remains a significant threat, putting 170\u2013300 million carriers worldwide at risk of cirrhosis and hepatocellular carcinoma. Although the direct-acting antivirals targeting HCV replication have revolutionized the treatment of hepatitis C, several obstacles persist, including resistance development, potential side-effects and the prohibitive cost that limits their availability. Furthermore, treatment of HCV re-infection in liver transplantation remains a significant challenge. Developing novel antivirals that target viral entry could help expand the scope of HCV therapeutics and treatment strategies. Herein, we report (4R,6S)-2-dihydromenisdaurilide (DHMD), a natural butenolide, as an efficient inhibitor of HCV entry. Specifically, DHMD potently inhibited HCV infection at non-cytotoxic concentration. Examination on the viral life cycle demonstrated that DHMD selectively targeted the early steps of infection while leaving viral replication\/translation and assembly\/release unaffected. Furthermore, DHMD did not induce an antiviral interferon response. Mechanistic dissection of HCV entry revealed that DHMD could inactivate cell-free virus, abrogate viral attachment and inhibit viral entry\/fusion, with the most pronounced effect observed against the viral adsorption phase as validated using ELISA and confocal microscopy. Due to its potency, DHMD may be of value for further development as an entry inhibitor against HCV, particularly for application in transplant setting.<\/jats:p>","DOI":"10.1038\/srep29969","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T09:58:26Z","timestamp":1468835906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["(4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry"],"prefix":"10.1038","volume":"6","author":[{"given":"Chueh-Yao","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guey-Horng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alagie","family":"Jassey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hong","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ching","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Tzung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"key":"BFsrep29969_CR1","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang, T. J. & Ghany, M. G. Current and future therapies for hepatitis C virus infection. The New England journal of medicine 368, 1907\u20131917, 10.1056\/NEJMra1213651 (2013).","journal-title":"The New England journal of medicine"},{"key":"BFsrep29969_CR2","doi-asserted-by":"publisher","first-page":"g3308","DOI":"10.1136\/bmj.g3308","volume":"348","author":"ER Feeney","year":"2014","unstructured":"Feeney, E. R. & Chung, R. T. Antiviral treatment of hepatitis C. Bmj 348, g3308, 10.1136\/bmj.g3308 (2014).","journal-title":"Bmj"},{"key":"BFsrep29969_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/apt.13514","volume":"43","author":"D Banerjee","year":"2016","unstructured":"Banerjee, D. & Reddy, K. R. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary pharmacology & therapeutics 43, 674\u2013696, 10.1111\/apt.13514 (2016).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"BFsrep29969_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/phar.1700","volume":"36","author":"P Deming","year":"2016","unstructured":"Deming, P. et al. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 36, 203\u2013217, 10.1002\/phar.1700 (2016).","journal-title":"Pharmacotherapy"},{"key":"BFsrep29969_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2217\/fvl.13.11","volume":"8","author":"M Lemoine","year":"2013","unstructured":"Lemoine, M., Nayagam, S. & Thursz, M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future virology 8, 371\u2013380, 10.2217\/fvl.13.11 (2013).","journal-title":"Future virology"},{"key":"BFsrep29969_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli, A., Shaffer, A., Sherman, A. & Kottilil, S. Treatment of hepatitis C: a systematic review. Jama 312, 631\u2013640, 10.1001\/jama.2014.7085 (2014).","journal-title":"Jama"},{"key":"BFsrep29969_CR7","first-page":"256","volume":"40","author":"D Gritsenko","year":"2015","unstructured":"Gritsenko, D. & Hughes, G. Ledipasvir\/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P & T: a peer-reviewed journal for formulary management 40, 256\u2013276 (2015).","journal-title":"P & T: a peer-reviewed journal for formulary management"},{"key":"BFsrep29969_CR8","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1128\/AAC.02605-15","volume":"60","author":"A Khatri","year":"2016","unstructured":"Khatri, A. et al. Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz and Rilpivirine. Antimicrobial agents and chemotherapy 60, 2965\u20132971, 10.1128\/AAC.02605-15 (2016).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep29969_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.chom.2014.10.009","volume":"16","author":"Q Ding","year":"2014","unstructured":"Ding, Q., von Schaewen, M. & Ploss, A. The impact of hepatitis C virus entry on viral tropism. Cell host & microbe 16, 562\u2013568, 10.1016\/j.chom.2014.10.009 (2014).","journal-title":"Cell host & microbe"},{"key":"BFsrep29969_CR10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jhep.2014.06.031","volume":"61","author":"J Dubuisson","year":"2014","unstructured":"Dubuisson, J. & Cosset, F. L. Virology and cell biology of the hepatitis C virus life cycle\u2013an update. Journal of hepatology 61, S3\u2013S13, 10.1016\/j.jhep.2014.06.031 (2014).","journal-title":"Journal of hepatology"},{"key":"BFsrep29969_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/2225-4110.124335","volume":"4","author":"LT Lin","year":"2014","unstructured":"Lin, L. T., Hsu, W. C. & Lin, C. C. Antiviral natural products and herbal medicines. Journal of traditional and complementary medicine 4, 24\u201335, 10.4103\/2225-4110.124335 (2014).","journal-title":"Journal of traditional and complementary medicine"},{"key":"BFsrep29969_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/np9600560","volume":"59","author":"J Qian-Cutrone","year":"1996","unstructured":"Qian-Cutrone, J. et al. Niruriside, a new HIV REV\/RRE binding inhibitor from Phyllanthus niruri. Journal of natural products 59, 196\u2013199, 10.1021\/np9600560 (1996).","journal-title":"Journal of natural products"},{"key":"BFsrep29969_CR13","doi-asserted-by":"publisher","first-page":"259103","DOI":"10.1093\/ecam\/nep157","volume":"2011","author":"HY Cheng","year":"2011","unstructured":"Cheng, H. Y. et al. Excoecarianin, Isolated from Phyllanthus urinaria Linnea, Inhibits Herpes Simplex Virus Type 2 Infection through Inactivation of Viral Particles. Evidence-based complementary and alternative medicine: eCAM 2011, 259103, 10.1093\/ecam\/nep157 (2011).","journal-title":"Evidence-based complementary and alternative medicine: eCAM"},{"key":"BFsrep29969_CR14","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1021\/jo5004604","volume":"79","author":"JJ Lv","year":"2014","unstructured":"Lv, J. J. et al. Anti-hepatitis B virus norbisabolane sesquiterpenoids from Phyllanthus acidus and the establishment of their absolute configurations using theoretical calculations. The Journal of organic chemistry 79, 5432\u20135447, 10.1021\/jo5004604 (2014).","journal-title":"The Journal of organic chemistry"},{"key":"BFsrep29969_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1089\/aid.1992.8.1937","volume":"8","author":"T Ogata","year":"1992","unstructured":"Ogata, T. et al. HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri. AIDS research and human retroviruses 8, 1937\u20131944 (1992).","journal-title":"AIDS research and human retroviruses"},{"key":"BFsrep29969_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5582\/ddt.2013.v7.6.212","volume":"7","author":"FH Qi","year":"2013","unstructured":"Qi, F. H. et al. Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection. Drug discoveries & therapeutics 7, 212\u2013224 (2013).","journal-title":"Drug discoveries & therapeutics"},{"key":"BFsrep29969_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/np7007347","volume":"71","author":"P Tuchinda","year":"2008","unstructured":"Tuchinda, P. et al. Dichapetalin-type triterpenoids and lignans from the aerial parts of Phyllanthus acutissima. Journal of natural products 71, 655\u2013663, 10.1021\/np7007347 (2008).","journal-title":"Journal of natural products"},{"key":"BFsrep29969_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.antiviral.2016.03.012","volume":"130","author":"CY Chung","year":"2016","unstructured":"Chung, C. Y. et al. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Antiviral research 130, 58\u201368, 10.1016\/j.antiviral.2016.03.012 (2016).","journal-title":"Antiviral research"},{"key":"BFsrep29969_CR19","doi-asserted-by":"crossref","unstructured":"Tai, C. J., Li, C. L., Tai, C. J., Wang, C. K. & Lin, L. T. Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds. Journal of visualized experiments: JoVE, e53124, 10.3791\/53124 (2015).","DOI":"10.3791\/53124"},{"key":"BFsrep29969_CR20","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/hep.22550","volume":"48","author":"S Marukian","year":"2008","unstructured":"Marukian, S. et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48, 1843\u20131850, 10.1002\/hep.22550 (2008).","journal-title":"Hepatology"},{"key":"BFsrep29969_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jhep.2014.10.040","volume":"62","author":"LT Lin","year":"2015","unstructured":"Lin, L. T. et al. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. Journal of hepatology 62, 541\u2013548, 10.1016\/j.jhep.2014.10.040 (2015).","journal-title":"Journal of hepatology"},{"key":"BFsrep29969_CR22","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1128\/JVI.01492-10","volume":"85","author":"LT Lin","year":"2011","unstructured":"Lin, L. T. et al. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. Journal of virology 85, 4386\u20134398, 10.1128\/JVI.01492-10 (2011).","journal-title":"Journal of virology"},{"key":"BFsrep29969_CR23","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1128\/JVI.00559-10","volume":"84","author":"LT Lin","year":"2010","unstructured":"Lin, L. T. et al. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. Journal of virology 84, 9170\u20139180, 10.1128\/JVI.00559-10 (2010).","journal-title":"Journal of virology"},{"key":"BFsrep29969_CR24","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/hep.24610","volume":"54","author":"S Ciesek","year":"2011","unstructured":"Ciesek, S. et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54, 1947\u20131955, 10.1002\/hep.24610 (2011).","journal-title":"Hepatology"},{"key":"BFsrep29969_CR25","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1128\/AAC.00633-11","volume":"55","author":"P Meuleman","year":"2011","unstructured":"Meuleman, P. et al. Griffithsin has antiviral activity against hepatitis C virus. Antimicrobial agents and chemotherapy 55, 5159\u20135167, 10.1128\/AAC.00633-11 (2011).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep29969_CR26","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1053\/j.gastro.2012.03.036","volume":"143","author":"S Haid","year":"2012","unstructured":"Haid, S. et al. A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology 143, 213-222 e215, 10.1053\/j.gastro.2012.03.036 (2012).","journal-title":"Gastroenterology"},{"key":"BFsrep29969_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2180-13-187","volume":"13","author":"LT Lin","year":"2013","unstructured":"Lin, L. T. et al. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC microbiology 13, 187, 10.1186\/1471-2180-13-187 (2013).","journal-title":"BMC microbiology"},{"key":"BFsrep29969_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/gutjnl-2012-304299","volume":"63","author":"Anggakusuma","year":"2014","unstructured":"Anggakusuma et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 63, 1137\u20131149, 10.1136\/gutjnl-2012-304299 (2014).","journal-title":"Gut"},{"key":"BFsrep29969_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.antiviral.2015.04.003","volume":"118","author":"WC Hsu","year":"2015","unstructured":"Hsu, W. C. et al. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Antiviral research 118, 139\u2013147, 10.1016\/j.antiviral.2015.04.003 (2015).","journal-title":"Antiviral research"},{"key":"BFsrep29969_CR30","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/np970341z","volume":"61","author":"T Ishikawa","year":"1998","unstructured":"Ishikawa, T., Nishigaya, K., Uchikoshi, H. & Cheng, I. S. Cochinolide, a new gamma-alkylidene bicyclic butenolide with antiviral activity and its beta-glucopyranoside from Homalium cochinchinensis. Journal of natural products 61, 534\u2013537, 10.1021\/np970341z (1998).","journal-title":"Journal of natural products"},{"key":"BFsrep29969_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1055\/s-2005-864142","volume":"71","author":"HJ Zhang","year":"2005","unstructured":"Zhang, H. J. et al. Sesquiterpenes and butenolides, natural anti-HIV constituents from Litsea verticillata. Planta medica 71, 452\u2013457, 10.1055\/s-2005-864142 (2005).","journal-title":"Planta medica"},{"key":"BFsrep29969_CR32","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.bmcl.2013.01.051","volume":"23","author":"H Gao","year":"2013","unstructured":"Gao, H. et al. Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity. Bioorganic & medicinal chemistry letters 23, 1776\u20131778, 10.1016\/j.bmcl.2013.01.051 (2013).","journal-title":"Bioorganic & medicinal chemistry letters"},{"key":"BFsrep29969_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/gutjnl-2013-306155","volume":"64","author":"F Xiao","year":"2015","unstructured":"Xiao, F. et al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 64, 483\u2013494, 10.1136\/gutjnl-2013-306155 (2015).","journal-title":"Gut"},{"key":"BFsrep29969_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0031-9422(93)85525-V","volume":"33","author":"H Otsuka","year":"1993","unstructured":"Otsuka, H., Ito, A., Fujioka, N., Kawamata, K. I., Kasai, R., Yamassaki, K. & Satoh, T. Butenolides from Sinomenium acutum. Phytochemistry 33, 389\u2013392 (1993).","journal-title":"Phytochemistry"},{"key":"BFsrep29969_CR35","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1073\/pnas.0800422105","volume":"105","author":"RS Russell","year":"2008","unstructured":"Russell, R. S. et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 105, 4370\u20134375, 10.1073\/pnas.0800422105 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep29969","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29969.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29969.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:28:04Z","timestamp":1672860484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep29969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,30]]}},"alternative-id":["BFsrep29969"],"URL":"https:\/\/doi.org\/10.1038\/srep29969","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,18]]},"assertion":[{"value":"15 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29969"}}